We have FDA orphan disease recognition.
A Ph3 trial does not have to be thousands, or even hundreds of patients.
This will be fast-tracked. Plus, we have funds.
And the idea all along has been to license the DM Ph3.
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-31
-
- There are more pages in this discussion • 256 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
-0.015(3.06%) |
Mkt cap ! $261.3M | |||
| Open | High | Low | Value | Volume |
| 49.5¢ | 49.5¢ | 46.5¢ | $2.742M | 5.746M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 158396 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 162500 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |